3 documents found, page 1 of 1
Inhibitory activity of psilocybin/psilocin towards the enzymes of the cytochrom...
Brito-da-Costa, A. M.; Silva-Carvalho, M.; Dinis-Oliveira, R. J.; Madureira-Carvalho, Á.; Dias da Silva, D.Background: Psilocybin is a hallucinogen produced by several “magic mushrooms” [1,2]. This prodrug is rapidly metabolized in the organism by alkaline phosphatases and esterases into psilocin, the active drug [1,2]. A scientific gap exists regarding the possible interactions between psilocybin/psilocin and CYP450 enzymes. Since the binding of drugs to CYP450 enzymes can interfere with the metabolism of other sub...
Clinical and toxicological effects of GLP-1 agonists
Teixeira, M. J.; Dias da Silva, D.Background: Glucagon-like peptide-1 receptor (GLP-1) agonists have been investigated and applied for the treatment of type 2 diabetes mellitus (T2DM) and obesity due to their ability to increase glucose-dependent insulin secretion. However, due to their recent therapeutic use, less is known in what concerns the long-term toxicological effects of these medicines. Objective: Herein, we compiled the available info...
Assessment of the CYP450 inhibitory potential of LSD, 5-MeO-DMT and mescaline: ...
Silva-Carvalho, M.; Brito-da-Costa, A. M.; Dinis-Oliveira, R. J.; Madureira-Carvalho, Á.; Dias da Silva, D.Background: LSD, 5-MeO-DMT and mescaline are classic hallucinogens known for their recreational use, whose consumption increased in the last decades. Despite some available data on the toxicokinetics of these drugs, little is known about their CYP450 metabolism [1,2,3]. Nevertheless, this information is of crucial relevance to predict drug-drug interactions and understand toxicological phenomena, in particular ...